弗卢瓦斯塔丁:一种选择,用于COVID-19相关的粘性菌根病管理
Alireza Tavakkoli1, Thomas P Johnston2, Amirhossein Sahebkar3,4,5,6
1Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Current medicinal chemistry
|July 7, 2023
概括
弗卢瓦斯塔丁在COVID-19患者中显示出作为抗真菌剂的潜力,特别是那些有粘膜菌风险的人. 与其他类他类药物相比,它具有较少的药物相互作用,具有协同抗真菌活性.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- 感染SARS-CoV-2可以导致全身炎症和二次感染,如粘膜菌.
- 在COVID-19患者中使用皮质类固醇会增加侵入性真菌感染的风险.
- 类药物在改善COVID-19患者的治疗结果方面表现有前途.
研究的目的:
- 在COVID-19的背景下,评估fluvastatin作为潜在的抗真菌剂.
- 评估fluvastatin的协同抗真菌活性和药物相互作用概况.
主要方法:
- 对弗卢瓦斯塔丁抗真菌性质的临床前报告的审查.
- 分析弗鲁瓦斯塔丁与COVID-19患者和免疫受损患者常用的常用药物的药物相互作用概况.
主要成果:
- 临床前数据表明,弗鲁瓦斯塔丁具有直接和间接的协同抗真菌活性.
- 与其他与抗Mucorales醇和免疫抑制剂的他类药物相比,Fluvastatin的药物相互作用较少.
结论:
- 弗卢瓦斯塔丁是一种潜在的抗真菌药物,可用于COVID-19相关的粘膜菌,特别是当其他选择有限时.
- 其有利的药物相互作用特征使其适用于高风险患者群体,包括移植接受者和艾滋病毒阳性个体.
相关概念视频
Cystic Fibrosis: Management
195
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
195
Endocarditis III: Medical Management
8
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
8
Pneumonia IV: Management
367
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
367
Myocarditis III: Medical Management
9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Endocarditis IV: Nursing Management
16
Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
16


